Curis Inc. (NASDAQ: CRIS) stock jumped 7.23% on Monday to $0.75 against a previous-day closing price of $0.70. With 1.03 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.84 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.7700 whereas the lowest price it dropped to was $0.6810. The 52-week range on CRIS shows that it touched its highest point at $3.76 and its lowest point at $0.47 during that stretch. It currently has a 1-year price target of $6.75. Beta for the stock currently stands at 2.89.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRIS was up-trending over the past week, with a rise of 2.89%, but this was up by 54.44% over a month. Three-month performance surged to 5.50% while six-month performance fell -32.38%. The stock lost -76.17% in the past year, while it has gained 36.47% so far this year. A look at the trailing 12-month EPS for CRIS yields -0.64 with Next year EPS estimates of -0.43. For the next quarter, that number is -0.13. This implies an EPS growth rate of 19.30% for this year and 30.60% for next year.
Float and Shares Shorts:
At present, 93.79 million CRIS shares are outstanding with a float of 90.67 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.96 million, which was 4.31% higher than short shares on Sep 14, 2022. In addition to Mr. James E. Dentzer as the firm’s Pres, CEO & Director, Dr. Robert E. Martell M.D., Ph.D. serves as its Head of R&D.
Through their ownership of 48.60% of CRIS’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 5.54% of CRIS, in contrast to 28.43% held by mutual funds. Shares owned by individuals account for 0.25%. As the largest shareholder in CRIS with 7.98% of the stake, Maverick Capital Ltd. holds 7,693,022 shares worth 7,693,022. A second-largest stockholder of CRIS, Nantahala Capital Management LLC, holds 3,420,510 shares, controlling over 3.55% of the firm’s shares. Kingdon Capital Management LLC is the third largest shareholder in CRIS, holding 2,524,424 shares or 2.62% stake. With a 1.92% stake in CRIS, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,852,559 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.09% of CRIS stock, is the second-largest Mutual Fund holder. It holds 1,054,023 shares valued at 0.58 million. Fidelity Extended Market Index Fu holds 0.44% of the stake in CRIS, owning 421,177 shares worth 0.23 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRIS since 5 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CRIS analysts setting a high price target of $10.00 and a low target of $3.00, the average target price over the next 12 months is $6.75. Based on these targets, CRIS could surge 1233.33% to reach the target high and rise by 300.0% to reach the target low. Reaching the average price target will result in a growth of 800.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CRIS will report FY 2022 earnings on 02/23/2024. Analysts have provided yearly estimates in a range of -$0.60 being high and -$0.63 being low. For CRIS, this leads to a yearly average estimate of -$0.62. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Curis Inc. surprised analysts by $0.03 when it reported -$0.14 EPS against a consensus estimate of -$0.17. The surprise factor in the prior quarter was -$0.00. Based on analyst estimates, the high estimate for the next quarter is -$0.10 and the low estimate is -$0.14. The average estimate for the next quarter is thus -$0.13.
Summary of Insider Activity:
Insiders traded CRIS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 0 while 5,500 shares were sold.